Our results support a cancer model whereby TREX1 upregulation is associated with chemotherapy resistance, as well as resistance to chemoimmunotherapy or ICB therapies by suppressing cGAS-STING-dependent innate immune response. The gene discussed is STING1; the disease is cancer.